TIGIT and plasma cell myeloma: Currently, nine human anti-TIGIT mAbs are being tested in 43 phase 1/2/3 clinical trials either as a monotherapy or, in most studies, in combination with anti-PD-1/PD-L1 antibodies or chemotherapies for the treatment of advanced solid tumors, and in two trials in multiple myeloma (Table 1).